ICU Stock Overview
A medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
SeaStar Medical Holding Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.05 |
| 52 Week High | US$42.92 |
| 52 Week Low | US$1.83 |
| Beta | -1.06 |
| 11 Month Change | -42.58% |
| 3 Month Change | -64.10% |
| 1 Year Change | -77.90% |
| 33 Year Change | -99.18% |
| 5 Year Change | n/a |
| Change since IPO | -99.16% |
Recent News & Updates
Recent updates
Shareholder Returns
| ICU | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -6.4% | 1.5% | 2.2% |
| 1Y | -77.9% | 20.8% | 31.6% |
Return vs Industry: ICU underperformed the US Medical Equipment industry which returned 20.9% over the past year.
Return vs Market: ICU underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| ICU volatility | |
|---|---|
| ICU Average Weekly Movement | 11.8% |
| Medical Equipment Industry Average Movement | 8.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ICU's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ICU's weekly volatility has decreased from 21% to 12% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 12 | Eric Schlorff | www.seastarmedical.com |
SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome.
SeaStar Medical Holding Corporation Fundamentals Summary
| ICU fundamental statistics | |
|---|---|
| Market cap | US$8.94m |
| Earnings (TTM) | -US$29.67m |
| Revenue (TTM) | US$68.00k |
131.5x
P/S Ratio-0.3x
P/E RatioIs ICU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ICU income statement (TTM) | |
|---|---|
| Revenue | US$68.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$68.00k |
| Other Expenses | US$29.74m |
| Earnings | -US$29.67m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.80 |
| Gross Margin | 100.00% |
| Net Profit Margin | -43,638.24% |
| Debt/Equity Ratio | 0% |
How did ICU perform over the long term?
See historical performance and comparison